Latest asthma Stories

OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on...

NATICK, Mass., May 21, 2013 /PRNewswire/ -- Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair(® )Bronchial Thermoplasty (BT) System continues to show therapy benefits in adult patients with severe uncontrolled asthma. Bronchial Thermoplasty was shown to provide long term asthma control, demonstrated by a sustained reduction in the rate of severe exacerbations (asthma...

Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils PARIS and TARRYTOWN, N.Y., May 21, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine published online the positive Phase 2a study results of dupilumab (SAR231893/REGN668) in patients with...

Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...

--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's lead compound in development for asthma and chronic obstructive pulmonary disease...

MADISON, Wis., May 20, 2013 /PRNewswire/ -- Asthmapolis (az-MAP-o-lis), the FDA-cleared mobile health solution for asthma and COPD, today announced CEO David Van Sickle will give an invited presentation during Respiratory Drug Delivery (RDD(®)) Europe 2013 in Berlin, Germany. On Friday, May 24 at 8:30 a.m., Van Sickle will present "Monitoring and Improving Compliance and Asthma Control: Mapping Inhaler Use for Feedback to Patients, Physicians and Payers" as part of the session track,...

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

Filtersfast.com is proud to introduce the addition of the new Lysol® Triple Protection™ Air Filters. Lysol® Air Filters do not contain scents that can trigger problems associated with asthma and allergy symptoms. Charlotte, NC (PRWEB) May 16, 2013 From the leading online retailer in air filters and water filters, Filtersfast.com introduces the first ever asthma and allergy friendly air filters, certified by the Asthma and Allergy Foundation of America. Lysol®, the same...

To celebrate Asthma Awareness Month, CascadeBreath of Bend, OR is offering $100 off all Asthma Relief Programs through June 14. It's time to control your asthma and CascadeBreath is prepared to guarantee it. Bend, Oregon (PRWEB) May 16, 2013 May is Asthma Awareness Month and CascadeBreath of Bend, OR is pleased to support the Global Initiative for Asthma's initiative “It's time to control your asthma.” To celebrate this initiative, CascadeBreath is offering $100 off all...

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound,...